Genelink

GeneLink, Inc. is engaged in the development of genetics-based assessment products for pharmaceutical applications and DNA storage purpose. The company is headquartered in Elmsford, New York. The company went IPO on 2000-03-09. The firm offers a range of commercially available modifications, fluorescently labeled probes, and specialized probes, such as Molecular Beacons, TaqMan, and Fluorescence resonance energy transfer (FRET), as well as a variety of other molecular biology products, such as linkers, adaptors, deoxyribonucleic acid (DNA) purification and clean-up kits. The Company’s product line of gene detection systems comprises reagents and reagent systems for scientists in the detection of genetic disorders. The firm focuses on triple repeat disorders, which include fragile x, myotonic dystrophy, huntington's disease. The company also specializes in the synthesis of ribonucleic acid (RNA) modified oligos, RNA fluorescent probes with quenchers, chimeric oligos containing various combinations of DNA, 2'O methyl or chimerics. The firm serves various industries, including research institutes, pharmaceutical companies and hospitals.